Kiyoshi Furuichi

Title: **Kiyoshi Furuichi: Innovator in Protein Engineering**

Introduction

Kiyoshi Furuichi, hailing from Saitama, Japan, is a notable inventor known for his contributions to the field of molecular biology and protein engineering. With a total of two patents to his name, he has significantly advanced the understanding and application of proteins relevant to human health.

Latest Patents

Furuichi's latest patents focus on the human MACIF (Membrane Attack Complex Inhibition Factor) activity. The first patent includes genes coding for a protein with human MACIF activity, expression vectors containing the aforementioned genes, and transformed cells that utilize these vectors. Furthermore, this patent involves the proteins that exhibit human MACIF activity. The second notable patent presents a fusion protein that combines the extracellular domain of the human MACIF gene product with a heterologous phosphatidylinositol (PI) anchor domain. This innovative approach showcases the application of protein fusion technology, which can potentially lead to new therapies and treatments.

Career Highlights

Kiyoshi Furuichi has made significant strides in his career by working with prominent pharmaceutical companies, specifically Yamanouchi Pharmaceutical Company Ltd. His work has garnered attention within the scientific community, owing to its potential implications in medical research and therapeutic development.

Collaborations

Throughout his career, Furuichi has collaborated with esteemed colleagues, including Motowo Tomita and Yuji Sugita. These partnerships have fostered a collaborative environment that encourages innovative research and development in the field of protein engineering.

Conclusion

Kiyoshi Furuichi's contributions to the realm of inventions and patents related to protein engineering exemplify the critical role inventors play in advancing scientific knowledge. His work continues to influence research and development, paving the way for future breakthroughs in healthcare and biotechnology.